Skip Navigation LinksHome > April 2014 - Volume 26 - Issue 2 > Neuroprotective effects of erythropoiesis-stimulating agents...
Current Opinion in Pediatrics:
doi: 10.1097/MOP.0000000000000077
NEONATOLOGY AND PERINATOLOGY: Edited by Richard A. Polin and Tara M. Randis

Neuroprotective effects of erythropoiesis-stimulating agents in term and preterm neonates

Messier, Amber M.; Ohls, Robin K.

Collapse Box

Abstract

Purpose of review

The use of erythropoiesis-stimulating agents (ESAs) such as erythropoietin and darbepoetin in preterm and term infants has been studied for over 20 years. Recent investigations have explored the potential neuroprotective effects of ESAs. We review the recent clinical trials and experimental animal models that provide evidence in support of using ESA to improve the neurodevelopmental outcomes in term and preterm infants.

Recent findings

Continued work using animal models have confirmed the neuroprotective properties of ESAs, including promotion of oligodendrocyte development in the face of neuronal injury. Clinical studies in term and preterm infants have reported the neuroprotective effects following ESA administration, and improved neurodevelopmental outcomes have been reported in the studies of preterm infants.

Summary

ESAs show great promise in preventing and treating brain injury in term and preterm infants.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.